Table 3.
Haplotype3 | Frequency | Cases | Controls |
Base model1 |
Full model2 |
||||
OR | 95% CI | P | OR | 95% CI | P | ||||
A-G-T-C | 0.180 | 146 (48.2) | 157 (51.8) | 1.16 | 0.865-1.550 | 0.32 | 1.05 | 0.751-1.456 | 0.79 |
C-C-T-C | 0.079 | 53 (48.2) | 57 (51.8) | 0.98 | 0.643-1.485 | 0.91 | 1.04 | 0.642-1.669 | 0.89 |
C-G-C-C | 0.184 | 88 (42.1) | 121 (57.9) | 0.76 | 0.548-1.060 | 0.11 | 0.94 | 0.645-1.356 | 0.72 |
C-G-C-T | 0.151 | 71 (52.6) | 64 (47.4) | 1.44 | 0.979-0.106 | 0.06 | 1.31 | 0.849-2.029 | 0.22 |
C-G-T-C | 0.398 | 58 (41.1) | 83 (58.9) | 0.75 | 0.510-1.089 | 0.13 | 0.70 | 0.449-1.082 | 0.11 |
Base model adjusted for age, gender and race;
Full model further adjusted for BMI, family history of colorectal cancer, NSAID use, and physical activity based on 329 cases and 390 controls;
Five other haplotypes representing a total of six participants were removed due to rarity.